Loading...
Market
Story
Home-Based Brain Stimulation Shows Promise for Treating Depression in 60% of Patients
Oct 21, 2024, 03:09 PM
A recent study has shown that home-based transcranial direct current stimulation (tDCS) can be an effective treatment for major depressive disorder. The fully remote phase 2 randomized sham-controlled trial demonstrated that tDCS, which delivers a small electrical current to the brain, has beneficial effects in cases of depression that do not respond to drugs or therapy. The study suggests that people with depression could administer brain stimulation at home, potentially offering a new avenue for treatment. The Flow tDCS headset, in particular, was highlighted, although some experts caution that the between-group difference in effectiveness is modest. British tabloid headlines claim that the headset 'eradicates' depression in 60% of patients.
View original story
Similar markets
Less than 10% • 25%
10% to 25% • 25%
26% to 50% • 25%
More than 50% • 25%
Company A • 25%
Company B • 25%
Company C • 25%
Other • 25%
0-10% • 25%
11-25% • 25%
26-50% • 25%
More than 50% • 25%
Company A • 25%
Company B • 25%
Company C • 25%
Other • 25%
PrecivityAD2™ dominates (>50%) • 25%
Sunbird Bio dominates (>50%) • 25%
Both share equally (~50% each) • 25%
Other diagnostic tests dominate • 25%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
UnitedHealth gains significant market share • 25%
Amedisys gains significant market share • 25%
Competitors gain significant market share • 25%
No significant change in market share • 25%
Less than 100 • 33%
100 to 500 • 33%
More than 500 • 33%
Less than 5 • 33%
5 to 10 • 33%
More than 10 • 33%
Less than 100 • 25%
100-500 • 25%
501-1000 • 25%
More than 1000 • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%